Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study
Osteoporosis International, 08/01/2011
Silverman SL et al. – The findings support a sustained anti-fracture effect of bazedoxifene on new vertebral fractures in postmenopausal osteoporotic women and on non-vertebral fractures in the higher-risk subgroup of women.
4,216 postmenopausal women with osteoporosis enrolled
2-year extension of 3-year, randomized, double-blind, placebo-controlled, phase 3 trial
In core study (N=7,492), subjects received bazedoxifene 20 or 40 mg/day, raloxifene 60 mg/day, or placebo
Raloxifene arm was discontinued after 3 years; subjects receiving bazedoxifene 40 mg were transitioned to bazedoxifene 20 mg after 4 years
5-year findings reported for bazedoxifene 20 and 40/20 mg and placebo
Endpoints included incidence of new vertebral fractures (primary) and non-vertebral fractures, and changes in BMD and bone turnover markers
At 5 years, the incidence of new vertebral fractures in the intent-to-treat population was significantly lower with bazedoxifene 20 mg (4.5%) and 40/20 mg (3.9%) versus placebo (6.8%; P<0.05), with relative risk reductions of 35% and 40%
Non-vertebral fracture incidence was similar among groups
In a subgroup of higher-risk women (n=1,324; femoral neck T-score ≤-3.0 and/or ≥1 moderate or severe or ≥2 mild vertebral fracture[s]), bazedoxifene 20 mg reduced non-vertebral fracture risk versus placebo (37%; P=0.06); combined data for bazedoxifene 20 and 40/20 mg reached statistical significance (34% reduction; P<0.05)
Bazedoxifene significantly increased BMD and reduced bone turnover versus placebo (P<0.05) and was generally safe and well tolerated
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.